News

Supernus Pharmaceuticals’ portfolio of Parkinson’s disease therapies now includes Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride), with the company’s acquisition of Adamas Pharmaceuticals now complete. “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” Jack Khattar, president and CEO of Supernus…

Aiming to improve the clinical outcomes of people with Parkinson’s disease, pharmaceutical company UCB is partnering with key U.K. and U.S. nonprofits to establish the Patient Engagement Council for Parkinson’s Research. UCB is teaming up with the Parkinson’s Foundation in the U.S. and Parkinson’s UK in launching…

People with early- or late-onset Parkinson’s disease tend to have different characteristic changes in their speech, according to a new study. The study, “Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease,” was published recently in npj Parkinson’s Disease. As many as nine in…

Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine — to explore conditions beyond essential tremor, including Parkinson’s disease and other neurological conditions. The funding also will help expand patient access to the company’s devices, which includes Cala Trio, a…

To heighten awareness and understanding of nonmotor Parkinson’s disease symptoms such as hallucinations and delusions, Acadia Pharmaceuticals and StoryCorps have teamed up to open Yours, Truly, a multicultural storytelling campaign. The national effort, which also seeks to reduce stigmas surrounding non-motor symptoms, is timed to National…

A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at Lund Universit’s strategic research area Multipark and senior attending physician at Skåne University Hospital,…

Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first clinical trial investigating the use of ketamine — a powerful anesthetic — as a treatment for depression in people with Parkinson’s disease. The study will be led by Sophie…

An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to the clinic and bring it one step closer to meeting the currently unaddressed needs…

Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of Fascinate’s request for such a trial, in the form of an investigational new…

The American Academy of Neurology (AAN) has issued a new group of guidelines designed to aid clinicians in prescribing the most effective and appropriate dopaminergic medications — those that increase or mimic dopamine — to patients in the early stages of Parkinson’s disease. The new guidelines, endorsed by…